Analysts have set 12-month price targets for Alkermes, revealing an average target of $42.0, a high estimate of $52.00, and a ...

Shares of Alkermes plc (NASDAQ:ALKS – Get Free Report) gapped up before the market opened on Thursday after Deutsche Bank Aktiengesellschaft raised their price target on the stock from $40.00 to ...

From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry ...

Mural Oncology (NASDAQ:MURA) stock plummets 47% as the company, a spinoff of Alkermes (ALKS) halts a Phase 3 trial for its ...

On St. Patrick's Day, everybody's a little Irish. Alkermes, Aon, Jazz Pharmaceuticals, PDD Holdings and CRH are five ...

Alkermes has said it is considering a spin-out ... to halt development of a BCL-2 inhibitor licensed from China's Fosun Pharma which had started phase 1 testing as a possible cancer drug, saying ...

Alkermes plc ALKS has made steady progress with its portfolio of proprietary products — Vivitrol (alcohol and opioid dependence), Aristada (schizophrenia) and Lybalvi (schizophrenia and bipolar ...

Alkermes belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Vertex Pharmaceuticals (VRTX), has gained 8.7% over the past month. More than a ...

Thrivent Financial for Lutherans reduced its position in Alkermes plc (NASDAQ:ALKS – Free Report) by 3.3% in the fourth ...

In a report released today, Jason Gerberry from Bank of America Securities maintained a Hold rating on Alkermes (ALKS – Research Report), with ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Vicarious Surgical (RBOT – Research Report), Alkermes (ALKS ...